📰We just published a #literature commentary on the evolving evidence in proton therapy in OPSCC and the @mdanderson.bsky.social study of Steven Frank including a critical perspective on the TORPEdO Trial - @england.nhs.uk
thoughts?
#ProtonTherapy #radonc
link.springer.com/content/pdf/...
🇩🇪🇫🇷 Caen - Marburg - Caen.
We had the pleasure to welcome Juliette Thariat to Marburg Ion-Beam Therapy Center MIT, @ukgm.bsky.social and @unimarburg.bsky.social
Great scientific exchange and valuable insights.
Looking forward to seeing you at PTCOG!
#healthcare #radonc #EU
🇩🇪🏴We had the pleasure to host Ioanna Nixon, for a week at MIT and Dept. Radiation Oncology Marburg within the HITRIplus #EU project.
A very thoughtful and inspiring scientific exchange, also on a personal level.
#healthcare #radonc #collaboration
@unimarburg.bsky.social @glasgow.ac.uk
Eid Mubarak 🇩🇪🇹🇷🇪🇬
In our truly #international and #diverse team - observing Ramadan (no water during day time!) while continuing to perform at the highest level is passion!
We celebrated together the end of Ramadan…really makes me proud to be a part of this🙌🏻
@ukgm.bsky.social
@unimarburg.bsky.social
⚡️Nice summary on RT effects on normal tissue from Deborah Citrin and Robert Timmerman in @nejm.org of medicine 🗞️
www.nejm.org/doi/abs/10.1...
#radonc #healthcare
@astro-org.bsky.social @myesmo.bsky.social @ascocancer.bsky.social
Panel A: The weekly Gravitrap Aedes aegypti index (GAI), which measures the abundance of adult A. aegypti mosquitoes, in the intervention and control clusters before and during the release of wolbachia-infected male mosquitoes. Panel B: A spatial visualization of the intervention (red) and control (teal) clusters.
In this report from Singapore, the release of wolbachia-infected, irradiated male 𝘈𝘦𝘥𝘦𝘴 𝘢𝘦𝘨𝘺𝘱𝘵𝘪 mosquitoes resulted in a reduction in the vector population and in the risk of dengue infection. Full report: nej.md/4atd2iN
#MedSky #IDSky
Phase III trial: Proton therapy (IMPT) is non-inferior to IMRT in oropharyngeal cancer, with better overall survival and significantly less tox, while maintaining similar disease control. ➡️ Supports IMPT
www.thelancet.com/journals/lan...
@thelancet.com @astro-org.bsky.social
#oncology #medicine
Clinical Practice Complex Regional Pain Syndrome An illustration of the symptoms and signs of complex regional pain syndrome in the affected limb. The NEJM identity sits at the bottom.
A new review summarizes the diagnosis and treatment of complex regional pain syndrome, a rare limb-pain disorder. Early rehabilitation and multidisciplinary care are key; most patients improve within 18 months. Read the Clinical Practice article: nej.md/3MSMW0n
@liverpooluni.bsky.social #MedSky
Found this gem from 1919 in our Department Library - #RadOnc Marburg 📚🩻
A dissertation “Die Behandlung der #Malaria mit X-Rays” (Berlin, 1919) — a fascinating window into the early history of #radiology after #WorldWar I.⭐️
@astro-org.bsky.social
@hmpxvt.bsky.social
@ascocancer.bsky.social
Not Otherwise Specified Episode 3.4 If You Break It, They Won’t Come
In the latest episode of the Not Otherwise Specified podcast, host Lisa Rosenbaum, MD, and her guests explore the fraught relationship between medical training and primary care — and why even trainees who once aspired to be PCPs are changing course midstream.
#MedSky
The latest podcast episode from our #ACROpolis partners at QuadShot News highlights the role of elective nodal treatment in bladder cancer, the impact of cribriform morphology on prostate cancer metastasis risk, and much more: podcasts.apple.com/us/podcast/1...
Conclusion:
⚡️& 🧪: Combinig RT with IO?
👉ESMO–ESTRO consensus statements on the safety of combining radiotherapy with IO, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors (TKI)
www.annalsofoncology.org/article/S092...
@myesmo.bsky.social @astro-org.bsky.social
#healthcare #cancerresearch
⚡️& 🧪: Combinig RT with IO?
👉ESMO–ESTRO consensus statements on the safety of combining radiotherapy with IO, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors (TKI)
www.annalsofoncology.org/article/S092...
@myesmo.bsky.social @astro-org.bsky.social
#healthcare #cancerresearch
Diagram explaining uveitis, an eye inflammation. It shows eye anatomy, uveitis types (anterior, intermediate, posterior, panuveitis), associated symptoms like redness and pain, and treatments including antibiotics and steroid eye drops. Untreated uveitis may cause vision loss.
Uveitis is a condition involving inflammation in the uvea (the middle portion of the eye).
📝 This JAMA Patient Page describes types of uveitis, ages and conditions associated with uveitis, and diagnosis and treatment.
ja.ma/48TW7a4
Original Article | Oct 30, 2025 A Randomized Trial of Physical Therapy for Meniscal Tear and Knee Pain Figure 1. Adjusted Mean KOOS Pain Subscores over Time. The NEJM identity sits at the bottom.
In the TeMPO trial, reduction in knee pain at 3 months was similar in participants assigned to home exercise alone and those assigned to home exercise, motivational text messages, and standard physical therapy. Full trial results: nej.md/4ofjqQt
#MedSky #Rheumatology
💪🏻 strong
American Society for Radiation Oncology (ASTRO) marks President Biden’s treatment milestone, highlighting #radiationtherapy’s vital role in prostate #cancer care 🎯
www.astro.org/news-and-pub...
#healthcare #oncology #radonc
@ascocancer.bsky.social @myesmo.bsky.social
A bar chart of the distribution of rare disease categories in the U.K. Biobank cohort.
Analyses of U.K. Biobank and clinical cohorts show that rare genetic diseases can be misdiagnosed as common diseases, which may have implications for clinical trials as well as for diagnosis and treatment. Full study results: nej.md/3Jk1MvD
#MedSky #Genetics
Incredible - 34thousand participants in Berlin💪🏻
#ESMO25: 177Lu-PSMA-617 with ADT plus ARPI showed PFS benefit in hormone-sensitive #ProstateCancer (#HSPC) but no improvement seen with 177Lu-PSMA-617 vs docetaxel in castration-resistant prostate cancer (#mCRPC) after ARPI.
#ESMODailyReporter ➡️ https://ow.ly/2C0e50XeAoj
📈Great Posters: EURO-ACT study atlas & ACCEPT program for Lung cancer patients
#ESMO2025 #ProstateCancer #NSCLC #RadiationOncology #Immunotherapy #ClinicalTrials
🫁 SKYSCRAPER-03 (Stage III NSCLC): Atezo+tira fails to beat durva after cCRT → durvalumab remains #standard.
MDT-BRIDGE (neo-IO NSCLC): High resection (85.7%) and R0 rates with close MDT guidance → more patients reach curative local #therapy.
#radonc Highlights from the last 24 hours at ESMO #Berlin 🚀
🌰ENZARAD (high-risk PCa): No overall MFS benefit with ENZA, but clear gains in cN1 & pelvic-RT subgroups.Selective intensification may matter
EMBARK (hrBCR PCa): Enza + ADT cuts mortality risk by ~40% vs ADT alone → a new standard of care
Figure. Addition of local consolidative therapy to osimertinib improved PFS versus osimertinib alone in patients with EGFR-mutated metastatic NSCLC in the NorthStar trial (ESMO Congress 2025, LBA72)
👇NorthStar trial - #ESMO highlight 17.10.
🧠 LCT improved PFS across subgroups
🌐 Even with >3 mets (20.7 vs 15.9 mo)
🧬 EGFR ex19del: 39.8 vs 22.8 mo
🔬 L858Rmut: 19.1 vs 11.0 mo
💪 Comprehensive vs partial LCT: 33.1 vs 15.1 mo
dailyreporter.esmo.org
@myesmo.bsky.social @astro-org.bsky.social
It was a pleasure to welcome the Nursing Directorate of Asklepios 👩⚕️👨⚕️ to our MIT - Marburg Ion-beam Therapy Center @ukgm.bsky.social 🏥!
Thx for the open discussions and the practical perspectives with a clear focus on #patientcare 💙.
#Healthcare #Collaboration #Innovation #HealthCareManagement
🌿 Science, collaboration & inspiration at Castle Rauischholzhausen 🏰 At the #ADMIT Summer School we explored medical physics & RT, shared ideas across disciplines & returned with fresh energy ✨ #Oncology #MedicalPhysics #Innovation
@ukgm.bsky.social @physics.bsky.social @unimarburg.bsky.social